Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin Phase Ib Study in Advanced Solid Tumors
NCT02496949Phase 1Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2011
- Primary completion
- May 2013
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Icaritin in solid tumor, breast cancer and hepatocellular carcinoma (HCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Number of patients reported adverse events. Started Nov 2011; status: completed.
02
Drugs
Icaritin
03
Conditions
solid tumorbreast cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02496949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02496949.